FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of October 2025
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Agreement with US Govt to lower medicine prices
13 October
2025
AstraZeneca announces historic agreement with US Government to
lower the cost of medicines for American patients
Delivers on all four of President Trump's requests reducing cost of
medicines
Preserves America's role as a global powerhouse in
biopharmaceuticals innovation
AstraZeneca to invest $50bn in manufacturing and R&D to support
domestic sourcing
AstraZeneca today announces a historic agreement with President
Donald J. Trump's administration to lower the cost of prescription
medicines for American patients while preserving America's
cutting-edge biopharmaceutical innovation.
At a landmark event at the White House, AstraZeneca CEO Pascal
Soriot joined President Trump and members of his Administration to
confirm the Company voluntarily met all requests set out in the
President's 31 July letter. The Company agrees to a range of
measures which will enable American patients to access medicines at
prices that are equalized with those available in wealthy
countries.
As part of the agreement, AstraZeneca will provide
Direct-to-Consumer (DTC) sales to eligible patients with
prescriptions for chronic diseases at a discount of up to 80% off
list prices. AstraZeneca will participate in the TrumpRx.gov direct
purchasing platform, which will allow patients to purchase
medicines at a reduced cash price from AstraZeneca.
AstraZeneca has also reached an agreement with the US Department of
Commerce to delay Section 232 tariffs for three years, enabling the
Company to fully onshore medicines manufacturing so that all of its
medicines sold in America are made in America. This will be
achieved through the Company's recently
announced $50 billion
investment in US medicines
manufacturing and R&D over the next five years to help deliver
$80 billion in Total Revenue by 2030, 50% of which is expected to
be generated in the US.
Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "Every
year AstraZeneca treats millions of Americans living with cancer
and chronic diseases and, as a result of today's agreement, many
patients will access life-changing medicines at lower prices. This
new approach also helps safeguard America's pioneering role as a
global powerhouse in innovation and developing the next generation
of medicines. It is now essential other wealthy countries step up
their contribution to fund innovation."
AstraZeneca's commitment to the US and American patients is further
reflected in the Company's largest single investment in a
manufacturing facility to date, where the Company broke ground
yesterday in Virginia. This facility will support AstraZeneca's
weight management and metabolic portfolio and our leading antibody
drug conjugate cancer pipeline. Additionally, a newly expanded
manufacturing facility in Coppell, Texas, will officially open next
week. Looking ahead, AstraZeneca will open a cell therapy
manufacturing facility in Rockville, Maryland early next year and
its second major R&D centre in Cambridge, Massachusetts will
open in late 2026.
The US is AstraZeneca's largest market by sales and is also home to
19 R&D, manufacturing and commercial sites. The Company's
US workforce exceeds more than 25,000 people and supports more than
100,000 jobs overall across the country. In 2025, AstraZeneca
created approximately $20 billion of overall value to the American
economy.
Notes
AstraZeneca's agreement with US Government
This is the second agreement that a pharmaceutical company has made
with the US Department of Health and Human Services to lower the
cost of medicines for American patients in the past two weeks.
Specific terms of this agreement remain confidential.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit astrazeneca.com and
follow the Company on social media @AstraZeneca.
The contents of AstraZeneca's website do not form part of this
document and no one should rely on such websites or the contents
thereof in reading this document.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Matthew Bowden
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
13 October 2025
|
|
By: /s/
Matthew Bowden
|
|
|
Name:
Matthew Bowden
|
|
|
Title:
Company Secretary
|
